Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04521621
Title A Study of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.

gastric adenocarcinoma

hypopharynx cancer

hepatocellular carcinoma

laryngeal squamous cell carcinoma

Advanced Solid Tumor

oropharynx cancer

gastroesophageal junction adenocarcinoma

head and neck squamous cell carcinoma

triple-receptor negative breast cancer

skin squamous cell carcinoma

oral squamous cell carcinoma


Coxsackievirus A21 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN

No variant requirements are available.